

## Bijlage 6. Literatuurlijst uitgangsvraag 1

1. Ivoren Kruis. Advies Droge mond. 2017.
2. Thomson WM, van der Putten GJ, de Baat C, Ikebe K, Matsuda K, Enoki K, et al. Shortening the xerostomia inventory. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2011;112(3):322-7.
3. Ichikawa K, Sakuma S, Yoshihara A, Miyazaki H, Funayama S, Ito K, et al. Relationships between the amount of saliva and medications in elderly individuals. *Gerodontology.* 2011;28(2):116-20.
4. Ikebe K, Nokubi T, Sajima H, Kobayashi S, Hata K, Ono T, et al. Perception of dry mouth in a sample of community-dwelling older adults in Japan. *Spec Care Dentist.* 2001;21(2):52-9.
5. Johanson CN, Osterberg T, Lernfelt B, Ekstrom J, Birkhed D. Salivary secretion and drug treatment in four 70-year-old Swedish cohorts during a period of 30 years. *Gerodontology.* 2015;32(3):202-10.
6. Tiisanoja A, Syrjala AM, Komulainen K, Hartikainen S, Taipale H, Knuuttila M, et al. Sedative load and salivary secretion and xerostomia in community-dwelling older people. *Gerodontology.* 2016;33(2):177-84.
7. Viljakainen S, Nykanen I, Ahonen R, Komulainen K, Suominen AL, Hartikainen S, et al. Xerostomia among older home care clients. *Community Dent Oral Epidemiol.* 2016;44(3):232-8.
8. Beau B, Mahieux F, Paraire M, Laurin S, Brisgand B, Vitou P. Efficacy and safety of rilmenidine for arterial hypertension. *Am J Cardiol.* 1988;61(7):95D-102D.
9. Blackwell B, Stefopoulos A, Enders P, Kuzma R, Adolphe A. Anticholinergic activity of two tricyclic antidepressants. *Am J Psychiatry.* 1978;135(6):722-4.
10. Cowman RA, Frisch M, Lasseter CJ, Scarpace PJ. Effects of beta-adrenergic antagonists on salivary secretory function in individuals of different ages. *J Gerontol.* 1994;49(5):B208-14.
11. Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. *Mayo Clin Proc.* 2003;78(6):687-95.
12. Handelman SL, Baric JM, Saunders RH, Espeland MA. Hyposalivatory drug use, whole stimulated salivary flow, and mouth dryness in older, long-term care residents. *Spec Care Dentist.* 1989;9(1):12-8.
13. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. *N Engl J Med.* 1979;300(23):1295-7.
14. Lam A, Kiyak A, Gossett AM, McCormick L. Assessment of the use of xerogenic medications for chronic medical and dental conditions among adult day health participants. *Consult Pharm.* 2009;24(10):755-64.
15. Lemberger L, Rowe H. Clinical pharmacology of nabilone, a cannabinol derivative. *Clin Pharmacol Ther.* 1975;18(6):720-6.
16. Lexomboon D, Tan EC, Hoijer J, Garcia-Ptacek S, Eriksdotter M, Religa D, et al. The Effect of Xerostomic Medication on Oral Health in Persons With Dementia. *J Am Med Dir Assoc.* 2018;19(12):1080-5.e2.
17. Locker D. Subjective reports of oral dryness in an older adult population. *Community Dent Oral Epidemiol.* 1993;21(3):165-8.
18. Lundstrom A, Eeg-Olofsson O, Hamp SE. Effects of anti-epileptic drug treatment with carbamazepine or phenytoin on the oral state of children and adolescents. *J Clin Periodontol.* 1982;9(6):482-8.
19. McMahon FG, Ryan JR, Jain AK, Vargas R, Vanov SK. Guanabenz in essential hypertension. *Clin Pharmacol Ther.* 1977;21(3):272-7.
20. Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, Francis GS, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. *Arch Neurol.* 1997;54(6):731-6.
21. Narhi TO. Prevalence of subjective feelings of dry mouth in the elderly. *J Dent Res.* 1994;73(1):20-5.
22. Nederfors T. Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists. *Swed Dent J Suppl.* 1996;116:1-70.

23. Nederfors T, Dahlof C, Ericsson T, Twetman S. Effects of the antihypertensive drug captopril on human salivary secretion rate and composition. *Eur J Oral Sci.* 1995;103(6):351-4.
24. Osterberg T, Landahl S, Hedegard B. Salivary flow, saliva, pH and buffering capacity in 70-year-old men and women. Correlation to dental health, dryness in the mouth, disease and drug treatment. *J Oral Rehabil.* 1984;11(2):157-70.
25. Ostermann G, Brisgand B, Schmitt J, Fillastre JP. Efficacy and acceptability of rilmenidine for mild to moderate systemic hypertension. *Am J Cardiol.* 1988;61(7):76D-80D.
26. Razani J, White KL, White J, Simpson G, Sloane RB, Rebal R, et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. *Arch Gen Psychiatry.* 1983;40(6):657-61.
27. Rickels K, Feighner JP, Smith WT. Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression. *Arch Gen Psychiatry.* 1985;42(2):134-41.
28. Rundegren J, van Dijken J, Mornstad H, von Knorring L. Oral conditions in patients receiving long-term treatment with cyclic antidepressant drugs. *Swed Dent J.* 1985;9(2):55-64.
29. Thomson WM, Brown RH, Williams SM. Medication and perception of dry mouth in a population of institutionalised elderly people. *N Z Med J.* 1993;106(957):219-21.
30. Vocci MJ, Robin AL, Wahl JC, Mayer P, Graves A, York B, et al. Reformulation and drop size of apraclonidine hydrochloride. *Am J Ophthalmol.* 1992;113(2):154-60.
31. Wilson MF, Haring O, Lewin A, Bedsole G, Stepansky W, Fillingim J, et al. Comparison of guanfacine versus clonidine for efficacy, safety and occurrence of withdrawal syndrome in step-2 treatment of mild to moderate essential hypertension. *Am J Cardiol.* 1986;57(9):43E-9E.
32. Abrams DA, Robin AL, Pollack IP, deFaller JM, DeSantis L. The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. *Arch Ophthalmol.* 1987;105(9):1205-7.
33. Abrams P, Cardozo L, Chapple C, Serdarevic D, Hargreaves K, Khullar V, et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. *Int J Urol.* 2006;13(6):692-8.
34. Aliko A, Wolff A, Dawes C, Aframian D, Proctor G, Ekstrom J, et al. World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2015;120(2):185-206.
35. Anderson RU, MacDiarmid S, Kell S, Barada JH, Serels S, Goldberg RP. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006;17(5):502-11.
36. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. *Mayo Clin Proc.* 2001;76(4):358-63.
37. Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. *Arch Gen Psychiatry.* 2003;60(11):1109-16.
38. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2008;372(9653):1906-13.
39. Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. *J Dent Res.* 2000;79(9):1652-8.
40. Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. *Am J Geriatr Psychiatry.* 2008;16(1):14-20.
41. Breuer MM, Mboya SA, Moroi H, Turesky SS. Effect of selected beta-blockers on supragingival calculus formation. *J Periodontol.* 1996;67(4):428-32.
42. Bruttman G, Charpin D, Germouty J, Horak F, Kunkel G, Wittmann G. Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis. *J Allergy Clin Immunol.* 1989;83(2 Pt 1):411-6.
43. Buchanan RW, Ball MP, Weiner E, Kirkpatrick B, Gold JM, McMahon RP, et al. Olanzapine treatment of residual positive and negative symptoms. *Am J Psychiatry.* 2005;162(1):124-9.
44. Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. *J Urol.* 2005;173(4):1214-8.

45. Casaburi R, Briggs DD, Jr., Donohue JF, Serby CW, Menjoge SS, Witek TJ, Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. *Chest*. 2000;118(5):1294-302.
46. Chancellor M, Versi E, Dvergsten C, Toler S. Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder. *J Urol*. 2015;194(5):1329-35.
47. Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. *Clin J Pain*. 2009;25(5):365-75.
48. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. *Neurology*. 2005;65(9):1423-9.
49. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. *Am J Psychiatry*. 1998;155(7):914-20.
50. Corli O, Roberto A, Bennett MI, Galli F, Corsi N, Rulli E, et al. Nonresponsiveness and Susceptibility of Opioid Side Effects Related to Cancer Patients' Clinical Characteristics: A Post-Hoc Analysis. *Pain pract*. 2018;18(6):748-57.
51. De Keyser P, Bouve J, Clement D, Degraef R, Meurant JP, Rorive G, et al. Isradipine in essential hypertension: the Belgian General Practitioners' Study. *Am J Med*. 1989;86(4A):103-9.
52. de Matos LF, Pereira SM, Kaminagakura E, Marques LS, Pereira CV, van der Bilt A, et al. Relationships of beta-blockers and anxiolytics intake and salivary secretion, masticatory performance and taste perception. *Arch Oral Biol*. 2010;55(2):164-9.
53. Djukic LJ, Roganovic J, Brajovic MD, Bokonjic D, Stojic D. The effects of anti-hypertensives and type 2 diabetes on salivary flow and total antioxidant capacity. *Oral Dis*. 2015;21(5):619-25.
54. Dmochowski RR, Davila GW, Zinner NR, Gittelman MC, Saltzstein DR, Lyttle S, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. *J Urol*. 2002;168(2):580-6.
55. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. *Lancet*. 2008;372(9634):207-15.
56. Erdemir U, Okan G, Gungor S, Tekin B, Yildiz SO, Yildiz E. The oral adverse effects of isotretinoin treatment in acne vulgaris patients: A prospective, case-control study. *Niger J Clin Pract*. 2017;20(7):860-6.
57. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiens ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet*. 2011;377(9774):1341-52.
58. Gourlay S, Forbes A, Marriner T, Kutin J, McNeil J. A placebo-controlled study of three clonidine doses for smoking cessation. *Clin Pharmacol Ther*. 1994;55(1):64-9.
59. Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot flashes: a randomized controlled trial. *Obstet Gynecol*. 2007;109(4):823-30.
60. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2010;376(9741):595-605.
61. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. *Lancet*. 1989;2(8672):1142-5.
62. Habbab KM, Moles DR, Porter SR. Potential oral manifestations of cardiovascular drugs. *Oral Dis*. 2010;16(8):769-73.
63. Hasan SS, Keong SC, Choong CL, Ahmed SI, Ching TW, Anwar M, et al. Patient-reported adverse drug reactions and drug-drug interactions: a cross-sectional study on Malaysian HIV/AIDS patients. *Med Princ Pract*. 2011;20(3):265-70.
64. Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, et al. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. *Cancer*. 2011;117(24):5469-75.

65. Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, et al. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. *J Urol*. 2010;183(5):1892-8.
66. Hsieh SG, Hibbert S, Shaw P, Ahern V, Arora M. Association of cyclophosphamide use with dental developmental defects and salivary gland dysfunction in recipients of childhood antineoplastic therapy. *Cancer*. 2011;117(10):2219-27.
67. Hurley DJ, Turner CL, Yalcin I, Viktrup L, Baygani SK. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. *Eur J Obstet Gynecol Reprod Biol*. 2006;125(1):120-8.
68. Jarernsiripornkul N, Krska J, Richards RM, Capps PA. Patient reporting of adverse drug reactions: useful information for pain management? *Eur J Pain*. 2003;7(3):219-24.
69. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. *Arch Gen Psychiatry*. 2001;58(10):965-72.
70. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. *J Urol*. 2005;174(6):2273-5. discussion 5-6.
71. Keenan RE, Black PL, Freudenburg JC, Hill JA, Holmburg CE, Reitbrock MJ, et al. Usefulness of low dose guanfacine, once a day, for 24-hour control of essential hypertension. *Am J Cardiol*. 1986;57(9):38E-42E.
72. Kesten S, Celli B, Decramer M, Leimer I, Tashkin D. Tiotropium HandiHaler in the treatment of COPD: a safety review. *Int J Chron Obstruct Pulmon Dis*. 2009;4:397-409.
73. Konstam MA, Gheorghiade M, Burnett JC, Jr., Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. *Jama*. 2007;297(12):1319-31.
74. Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, et al. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. *JAMA Neurol*. 2017;74(2):197-206.
75. Lenander-Lumikari M, Puhakka T, Makela MJ, Vilja P, Ruuskanen O, Tenovuo J. Effects of the common cold and intranasal fluticasone propionate treatment on mucosal host defense assessed by human saliva. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1999;87(6):695-9.
76. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. *Curr Med Res Opin*. 2008;24(7):1877-90.
77. Loesche WJ, Bromberg J, Terpenning MS, Bretz WA, Dominguez BL, Grossman NS, et al. Xerostomia, xerogenic medications and food avoidances in selected geriatric groups. *J Am Geriatr Soc*. 1995;43(4):401-7.
78. Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. *J Urol*. 2001;165(5):1452-6.
79. Marcus SM, Gorman J, Shear MK, Lewin D, Martinez J, Ray S, et al. A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy. *Am J Psychiatry*. 2007;164(2):273-5.
80. Mazzeo MA, Linares JA, Campos ML, Busamia BE, Dubersarsky C, Lavarda M, et al. Oral signs of intravenous chemotherapy with 5-Fluorouracil and Leucovorin calcium in colon cancer treatment. *Med Oral Patol Oral Cir Bucal*. 2009;14(3):E108-13.
81. Murray Thomson W, Chalmers JM, John Spencer A, Slade GD, Carter KD. A longitudinal study of medication exposure and xerostomia among older people. *Gerodontology*. 2006;23(4):205-13.
82. Murray Thomson W, Poulton R, Mark Broadbent J, Al-Kubaisy S. Xerostomia and medications among 32-year-olds. *Acta Odontol Scand*. 2006;64(4):249-54.
83. Nederfors T, Dahlof C. Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human whole saliva flow rate and composition. *Arch Oral Biol*. 1992;37(7):579-84.
84. Nederfors T, Henricsson V, Dahlof C, Axell T. Oral mucosal friction and subjective perception of dry mouth in relation to salivary secretion. *Scand J Dent Res*. 1993;101(1):44-8.



85. Oosten AW, Oldenmenger WH, Mathijssen RH, van der Rijt CC. A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures. *J Pain*. 2015;16(10):935-46.
86. Pascual Cruz M, Chimenos Kustner E, Garcia Vicente JA, Mezquiriz Ferrero X, Borrell Thio E, Lopez Lopez J. Adverse side effects of statins in the oral cavity. *Med Oral Patol Oral Cir Bucal*. 2008;13(2):E98-101.
87. Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. *N Engl J Med*. 2017;376(2):115-24.
88. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbhoff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. *Arch Gen Psychiatry*. 2005;62(9):1022-30.
89. Robin AL, Ritch R, Shin DH, Smythe B, Mundorf T, Lehmann RP. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group. *Am J Ophthalmol*. 1995;120(4):423-32.
90. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology*. 2005;65(6):812-9.
91. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. *Arch Ophthalmol*. 1997;115(7):847-52.
92. Silberstein S, Tepper S, Brandes J, Diamond M, Goldstein J, Winner P, et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. *Neurology*. 2004;62(9):1552-7.
93. Smidt D, Torpet LA, Nauntofte B, Heegaard KM, Pedersen AM. Associations between oral and ocular dryness, labial and whole salivary flow rates, systemic diseases and medications in a sample of older people. *Community Dent Oral Epidemiol*. 2011;39(3):276-88.
94. So JS, Chung SC, Kho HS, Kim YK, Chung JW. Dry mouth among the elderly in Korea: a survey of prevalence, severity, and associated factors. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2010;110(4):475-83.
95. Sreebny LM, Valdin A, Yu A. Xerostomia. Part II: Relationship to nonoral symptoms, drugs, and diseases. *Oral Surg Oral Med Oral Pathol*. 1989;68(4):419-27.
96. Stark JG, Engelking D, McMahan R, Sikes C. A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults. *Postgrad Med*. 2016;128(7):648-55.
97. Staskin D, Sand P, Zinner N, Dmochowski R, Trospium Study G. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. *J Urol*. 2007;178(3 Pt 1):978-83; discussion 83-4.
98. Tan ECK, Lexomboon D, Sandborgh-Englund G, Haasum Y, Johnell K. Medications That Cause Dry Mouth As an Adverse Effect in Older People: A Systematic Review and Metaanalysis. *J Am Geriatr Soc*. 2018;66(1):76-84.
99. Teivelis MP, Wolosker N, Krutman M, Milanez de Campos JR, Kauffman P, Puech-Leao P. Compensatory hyperhidrosis: results of pharmacologic treatment with oxybutynin. *Ann Thorac Surg*. 2014;98(5):1797-802.
100. Tinkelman DG, Bucholtz GA, Kemp JP, Koepke JW, Repsher LH, Spector SL, et al. Evaluation of the safety and efficacy of multiple doses of azelastine to adult patients with bronchial asthma over time. *Am Rev Respir Dis*. 1990;141(3):569-74.
101. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. *Am J Psychiatry*. 1999;156(5):702-9.
102. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. *Cmaj*. 1998;159(10):1245-52.
103. van Marion WF, Bongaerts MC, Christiaanse JC, Hofkamp HG, van Ouwkerk W. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas. *Clin Pharmacol Ther*. 1985;38(3):301-5.
104. Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. *Obstet Gynecol*. 2000;95(5):718-21.

105. Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, et al. Anticholinergic therapy vs. onabotulinumtoxicina for urgency urinary incontinence. *N Engl J Med.* 2012;367(19):1803-13.
106. Weber MA, Drayer JI. Treatment of hypertension in the elderly. *South Med J.* 1986;79(3):323-6.
107. Weintraub M, Ginsberg G, Stein EC, Sundaresan PR, Schuster B, O'Connor P, et al. Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification. *Clin Pharmacol Ther.* 1986;39(5):501-9.
108. Weintraub M, Sundaresan PR, Madan M, Schuster B, Balder A, Lasagna L, et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. *Clin Pharmacol Ther.* 1992;51(5):586-94.
109. Weintraub M, Sundaresan PR, Schuster B, Ginsberg G, Madan M, Balder A, et al. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. *Clin Pharmacol Ther.* 1992;51(5):595-601.
110. Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. *Depress Anxiety.* 2007;24(1):41-52.
111. Wolff A, Joshi RK, Ekstrom J, Aframian D, Pedersen AM, Proctor G, et al. A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. *Drugs R D.* 2017;17(1):1-28.
112. Wolff A, Zuk-Paz L, Kaplan I. Major salivary gland output differs between users and non-users of specific medication categories. *Gerodontology.* 2008;25(4):210-6.
113. Yanny B, Saab S, Durazo F, Latt N, Mitry A, Mikhail MM, et al. Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naive Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL. *Dig Dis Sci.* 2018;63(12):3480-6.
114. Zhang X, Zhao M, Du W, Zu D, Sun Y, Xiang R, et al. Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia: A Meta-Analysis. *Medicine (Baltimore).* 2016;95(15):e3310.
115. Galley P, Manciet G, Hessel JL, Michel JP. Antihypertensive efficacy and acceptability of rilmenidine in elderly hypertensive patients. *Am J Cardiol.* 1988;61(7):86D-90D.
116. Johnson MH, Nepple KG, Peck V, Trinkaus K, Klim A, Sandhu GS, et al. Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guerin treatment. *J Urol.* 2013;189(4):1268-74.
117. Smidt D, Torpet LA, Nauntofte B, Heegaard KM, Pedersen AM. Associations between labial and whole salivary flow rates, systemic diseases and medications in a sample of older people. *Community Dent Oral Epidemiol.* 2010;38(5):422-35.
118. Aantaa RE, Kanto JH, Scheinin M, Kallio AM, Scheinin H. Dexmedetomidine premedication for minor gynecologic surgery. *Anesth Analg.* 1990;70(4):407-13.
119. Acharya S, Pai KM, Bhat S, Mamatha B, Bejadi VM, Acharya S. Oral changes in patients undergoing chemotherapy for breast cancer. *Indian J Dent Res.* 2017;28(3):261-8.
120. Avsar A, Elli M, Darka O, Pinarli G. Long-term effects of chemotherapy on caries formation, dental development, and salivary factors in childhood cancer survivors. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2007;104(6):781-9.
121. Berger Velten D, Zandonade E, Monteiro de Barros Miotto MH. Prevalence of oral manifestations in children and adolescents with cancer submitted to chemotherapy. *BMC Oral Health.* 2016;16(1):107.
122. Brooks JO, 3rd, Goldberg JF, Ketter TA, Miklowitz DJ, Calabrese JR, Bowden CL, et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. *J Clin Psychiatry.* 2011;72(2):240-7.
123. Brindley MJ, Longman LP, Randall C, Field EA. Drug profile of adult patients attending five general dental practices in Merseyside: oral side-effects and potential interactions with dentally prescribed medication. *Prim Dent care.* 2003;10(4):113-8.
124. Chevalier M, Sakarovitch C, Precheur I, Lamure J, Pouyssegur-Rougier V. Antiseptic mouthwashes could worsen xerostomia in patients taking polypharmacy. *Acta Odontol Scand.* 2015;73(4):267-73.

125. Clague J, Belin TR, Shetty V. Mechanisms underlying methamphetamine-related dental disease. *J Am Dent Assoc.* 2017;148(6):377-86.
126. Cockburn N, Pateman K, Taing MW, Pradhan A, Ford PJ. Managing the oral side-effects of medications used to treat multiple sclerosis. *Aust Dent J.* 2017;62(3):331-6.
127. Collamati A, Martone AM, Poscia A, Brandi V, Celi M, Marzetti E, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. *Aging Clin Exp Res.* 2016;28(1):25-35.
128. de Almeida Pdel V, Gregio AM, Brancher JA, Ignacio SA, Machado MA, de Lima AA, et al. Effects of antidepressants and benzodiazepines on stimulated salivary flow rate and biochemistry composition of the saliva. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2008;106(1):58-65.
129. de Lima Saintrain MV, Goncalves RD. Salivary tests associated with elderly people's oral health. *Gerodontology.* 2013;30(2):91-7.
130. de Visser SJ, van der Post JP, Nanhekhani L, Schoemaker RC, Cohen AF, van Gerven JM. Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients. *Clin Pharmacol Ther.* 2002;72(4):419-28.
131. Deshpande MA, Holden RR, Gilron I. The impact of therapy on quality of life and mood in neuropathic pain: what is the effect of pain reduction? *Anesth Analg.* 2006;102(5):1473-9.
132. Diz Dios P, Scully C. Antiretroviral therapy: effects on orofacial health and health care. *Oral Dis.* 2014;20(2):136-45.
133. Du C, Ying H, Zhou J, Hu C, Zhang Y. Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma. *Int J Clin Oncol.* 2013;18(3):464-71.
134. Dubey S, Saha S, Tripathi AM, Bhattacharya P, Dhinsa K, Arora D. A comparative evaluation of dental caries status and salivary properties of children aged 5-14 years undergoing treatment for acute lymphoblastic leukemia, type I diabetes mellitus, and asthma - In vivo. *J Indian Soc Pedod Prev Dent.* 2018;36(3):283-9.
135. Evio S, Tarkkila L, Sorsa T, Furuholm J, Valimaki MJ, Ylikorkala O, et al. Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis. *Oral Dis.* 2006;12(2):187-93.
136. Field EA, Longman LP, Bucknall R, Kaye SB, Higham SM, Edgar WM. The establishment of a xerostomia clinic: a prospective study. *Br J Oral Maxillofac Surg.* 1997;35(2):96-103.
137. Field EA, Fear S, Higham SM, Ireland RS, Rostron J, Willetts RM, et al. Age and medication are significant risk factors for xerostomia in an English population, attending general dental practice. *Gerodontology.* 2001;18(1):21-4.
138. Fishman LM, Konnoth C, Rozner B. Botulinum neurotoxin type B and physical therapy in the treatment of piriformis syndrome: a dose-finding study. *Am J Phys Med Rehabil.* 2004;83(1):42-50; quiz 1-3.
139. Flink H. Studies on the prevalence of reduced salivary flow rate in relation to general health and dental caries, and effect of iron supplementation. *Swed Dent J Suppl.* 2007(192):3-50, 2 p preceding table of contents.
140. Flink H, Bergdahl M, Tegelberg A, Rosenblad A, Lagerlof F. Prevalence of hyposalivation in relation to general health, body mass index and remaining teeth in different age groups of adults. *Community Dent Oral Epidemiol.* 2008;36(6):523-31.
141. Fromm M, Littman P, Raney RB, Nelson L, Handler S, Diamond G, et al. Late effects after treatment of twenty children with soft tissue sarcomas of the head and neck. Experience at a single institution with a review of the literature. *Cancer.* 1986;57(10):2070-6.
142. Garcia-Chias B, Figuero E, Castelo-Fernandez B, Cebrian-Carretero JL, Cerero-Lapiedra R. Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study. *Support Care Cancer.* 2019;27(9):3479-90.
143. Garming-Legert K, Remberger M, Ringden O, Hassan M, Dahllof G. Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI. *Oral Dis.* 2011;17(7):670-6.
144. Goetz DW, Jacobson JM, Murnane JE, Reid MJ, Repperger DW, Goodyear C, et al. Prolongation of simple and choice reaction times in a double-blind comparison of twice-daily hydroxyzine versus terfenadine. *J Allergy Clin Immunol.* 1989;84(3):316-22.

145. Goldstein-Dresner MC, Davis PJ, Kretchman E, Siewers RD, Certo N, Cook DR. Double-blind comparison of oral transmucosal fentanyl citrate with oral meperidine, diazepam, and atropine as preanesthetic medication in children with congenital heart disease. *Anesthesiology*. 1991;74(1):28-33.
146. Groth ML, Langenback EG, Foster WM. Influence of inhaled atropine on lung mucociliary function in humans. *Am Rev Respir Dis*. 1991;144(5):1042-7.
147. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. *J Am Dent Assoc*. 2003;134(1):61-9; quiz 118-9.
148. Haber PS, Elsayed M, Espinoza D, Lintzeris N, Veillard AS, Hallinan R. Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. *Drug Alcohol Depend*. 2017;181:132-9.
149. Harnett MJ, O'Rourke N, Walsh M, Carabuena JM, Segal S. Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after cesarean delivery. *Anesth Analg*. 2007;105(3):764-9.
150. Hunter KD, Wilson WS. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. *Arch Oral Biol*. 1995;40(11):983-9.
151. Jankittivong A, Lin AL, Johnson DA, Langlais RP, Yeh CK. Salivary secretion, mucin concentrations and *Candida* carriage in HIV-infected patients. *Oral Dis*. 2009;15(3):229-34.
152. Kagawa R, Ikebe K, Enoki K, Murai S, Okada T, Matsuda K, et al. Influence of hypertension on pH of saliva in older adults. *Oral Dis*. 2013;19(5):525-9.
153. Kamikawa Y, Mori Y, Nagayama T, Fujisaki J, Hirabayashi D, Sakamoto R, et al. Frequency of clinically isolated strains of oral *Candida* species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013. *BMC Oral Health*. 2014;14:14.
154. Kaplan SA, Chughtai BI. Safety of Tamsulosin: A Systematic Review of Randomized Trials with a Focus on Women and Children. *Drug Saf*. 2018;41(9):835-42.
155. Karolewska E, Konopka T, Pupek M, Chybicka A, Mendak M. Antibacterial potential of saliva in children with leukemia. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2008;105(6):739-44.
156. Kaste SC, Goodman P, Leisenring W, Stovall M, Hayashi RJ, Yeazel M, et al. Impact of radiation and chemotherapy on risk of dental abnormalities: a report from the Childhood Cancer Survivor Study. *Cancer*. 2009;115(24):5817-27.
157. Ko KJ, Kim KH, Kim SW, Kim SO, Seo JT, Choo MS, et al. Efficacy and Safety of Tolterodine and Pilocarpine in Patients with Overactive Bladder. *J Urol*. 2019;202(3):564-73.
158. Kreher JM, Graser GN, Handelman SL. The relationship of drug use to denture function and saliva flow rate in a geriatric population. *J Prosthet Dent*. 1987;57(5):631-8.
159. Laine M, Leimola-Virtanen R. Effect of hormone replacement therapy on salivary flow rate, buffer effect and pH on perimenopausal and postmenopausal women. *Arch Oral Biol*. 1996;41(1):91-6.
160. Laine P, Meurman JH, Tenovuo J, Murtomaa H, Lindqvist C, Pyrhonen S, et al. Salivary flow and composition in lymphoma patients before, during and after treatment with cytostatic drugs. *Eur J Cancer B Oral Oncol*. 1992;28B(2):125-8.
161. Le QT, Kim HE, Schneider CJ, Murakozy G, Skladowski K, Reinisch S, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. *J Clin Oncol*. 2011;29(20):2808-14.
162. Leal SC, Bittar J, Portugal A, Falcao DP, Faber J, Zanotta P. Medication in elderly people: its influence on salivary pattern, signs and symptoms of dry mouth. *Gerodontology*. 2010;27(2):129-33.
163. Lin AL, Johnson DA, Sims CA, Stephan KT, Yeh CK. Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART). *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2006;102(3):318-24.
164. Lin AL, Johnson DA, Stephan KT, Yeh CK. Salivary secretory leukocyte protease inhibitor increases in HIV infection. *J Oral Pathol Med*. 2004;33(7):410-6.
165. Lin AL, Johnson DA, Stephan KT, Yeh CK. Alteration in salivary function in early HIV infection. *J Dent Res*. 2003;82(9):719-24.
166. Lone MA, Shaikh S, Lone MM, Afaq A, Lone MA. Association of salivary gland hypofunction with diabetes mellitus and drugs among the elderly in Karachi, Pakistan. *J*. 2017;8(2).
167. Mattes RD, Engelman K. Effects of combined hydrochlorothiazide and amiloride versus single drug on changes in salt taste and intake. *Am J Cardiol*. 1992;70(1):91-5.



168. Maupome G, Peters D, Rush WA, Rindal DB, White BA. The relationship between cardiovascular xerogenic medication intake and the incidence of crown/root restorations. *J Public Health Dent.* 2006;66(1):49-56.
169. Meek PD, Evang SD, Tadrous M, Roux-Lirange D, Triller DM, Gumustop B. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. *Dig Dis Sci.* 2011;56(1):7-18.
170. Meurman JH, Laine P, Keinanen S, Pyrhonen S, Teerenhovi L, Lindqvist C. Five-year follow-up of saliva in patients treated for lymphomas. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1997;83(4):447-52.
171. Meurman JH, Collin HL, Niskanen L, Toyry J, Alakuijala P, Keinanen S, et al. Saliva in non-insulin-dependent diabetic patients and control subjects: The role of the autonomic nervous system. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1998;86(1):69-76.
172. Nakano S, Hollister LE. Chronopharmacology of amitriptyline. *Clin Pharmacol Ther.* 1983;33(4):453-9.
173. Navazesh M, Mulligan R, Karim R, Mack WJ, Ram S, Seirawan H, et al. Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS). *Oral Dis.* 2009;15(1):52-60.
174. Navazesh M, Brightman VJ, Pogoda JM. Relationship of medical status, medications, and salivary flow rates in adults of different ages. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1996;81(2):172-6.
175. Nederfors T, Isaksson R, Mornstad H, Dahlof C. Prevalence of perceived symptoms of dry mouth in an adult Swedish population--relation to age, sex and pharmacotherapy. *Community Dent Oral Epidemiol.* 1997;25(3):211-6.
176. Nederfors T, Nauntofte B, Twetman S. Effects of furosemide and bendroflumethiazide on saliva flow rate and composition. *Arch Oral Biol.* 2004;49(7):507-13.
177. Niedermeier W, Huber M, Fischer D, Beier K, Muller N, Schuler R, et al. Significance of saliva for the denture-wearing population. *Gerodontology.* 2000;17(2):104-18.
178. Nishihara T, Suzuki N, Yoneda M, Hirofujii T. Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial. *BMC Oral Health.* 2014;14:110.
179. Nittayananta W, Talungchit S, Jaruratanasirikul S, Silpapojakul K, Chayakul P, Nilmanat A, et al. Effects of long-term use of HAART on oral health status of HIV-infected subjects. *J Oral Pathol Med.* 2010;39(5):397-406.
180. Pajukoski H, Meurman JH, Snellman-Grohn S, Keinanen S, Sulkava R. Salivary flow and composition in elderly patients referred to an acute care geriatric ward. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1997;84(3):265-71.
181. Patel PS, Ghezzi EM, Ship JA. Xerostomic complaints induced by an anti-sialogogue in healthy young vs. older adults. *Spec Care Dentist.* 2001;21(5):176-81.
182. Peker I, Alkurt MT, Usalan G. Clinical evaluation of medications on oral and dental health. *Int Dent J.* 2008;58(4):218-22.
183. Pereira LJ, Foureaux RC, Pereira CV, Alves MC, Campos CH, Rodrigues Garcia RC, et al. Oral physiology, nutrition and quality of life in diabetic patients associated or not with hypertension and beta-blockers therapy. *J Oral Rehabil.* 2016;43(7):511-8.
184. Persson RE, Izutsu KT, Treulove EL, Persson R. Differences in salivary flow rates in elderly subjects using xerostomatic medications. *Oral Surg Oral Med Oral Pathol.* 1991;72(1):42-6.
185. Pollock BG, Mulsant BH, Nebes R, Kirshner MA, Begley AE, Mazumdar S, et al. Serum anticholinergic activity in elderly depressed patients treated with paroxetine or nortriptyline. *Am J Psychiatry.* 1998;155(8):1110-2.
186. Rani PU, Naidu MU, Prasad VB, Rao TR, Shobha JC. An evaluation of antidepressants in rheumatic pain conditions. *Anesth Analg.* 1996;83(2):371-5.
187. Rheker J, Rief W, Doering BK, Winkler A. Assessment of adverse events in clinical drug trials: Identifying amitriptyline's placebo- and baseline-controlled side effects. *Exp Clin Psychopharmacol.* 2018;26(3):320-6.
188. Rosenberg SS, Kumar S, Williams NJ. Attention deficit/hyperactivity disorder medication and dental caries in children. *J Dent Hyg.* 2014;88(6):342-7.
189. Ryan J, Leighton J, Kirksey D, McMahan G. Evaluation of an enkephalin analog in men with castor oil-induced diarrhea. *Clin Pharmacol Ther.* 1986;39(1):40-2.

190. Sarkissian A, Neher JO, Singh R, St Anna L. Clinical Inquiry: Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? *J.* 2012;61(12):759-72.
191. Sarmento DJS, Caliento R, Souza AO, Tozetto-Mendoza TR, Palmieri M, Martins VAO, et al. Salivary shedding of herpesviruses in renal transplant recipients. *J.* 2018;9(4):e12356.
192. Scelza MF, Silva Dde F, Ahiadzro NK, Da Silva LE, Scelza P. The influence of medication on salivary flow of the elderly: preliminary study. *Gerodontology.* 2010;27(4):278-82.
193. Schulte B, Volz-Zang C, Mutschler E, Horne C, Palm D, Wellstein A, et al. AF-DX 116, a cardioselective muscarinic antagonist in humans: pharmacodynamic and pharmacokinetic properties. *Clin Pharmacol Ther.* 1991;50(4):372-8.
194. Scully C, Bagan JV. Adverse drug reactions in the orofacial region. *Crit Rev Oral Biol Med.* 2004;15(4):221-39.
195. Scully C. Drug effects on salivary glands: dry mouth. *Oral Dis.* 2003;9(4):165-76.
196. Scully C, El-Kabir M, Greenman J, Porter SR, Mutlu S, Barton I, et al. The effects of mouth rinses and dentifrice-containing magnesium monoperoxyphthalate (mmpp) on oral microflora, plaque reduction, and mucosa. *J Clin Periodontol.* 1999;26(4):234-8.
197. Seto BG, Kim M, Wolinsky L, Mito RS, Champlin R. Oral mucositis in patients undergoing bone marrow transplantation. *Oral Surg Oral Med Oral Pathol.* 1985;60(5):493-7.
198. Shade MY, Berger AM, Chaperon C, Haynatzki G, Sobeski L. Adverse drug events reported by rural older adults. *Geriatr Nurs.* 2017;38(6):584-8.
199. Sharma G, Pai KM, Suhas S, Ramapuram JT, Doshi D, Anup N. Oral manifestations in HIV/AIDS infected patients from India. *Oral Dis.* 2006;12(6):537-42.
200. Shinkai RS, Hatch JP, Schmidt CB, Sartori EA. Exposure to the oral side effects of medication in a community-based sample. *Spec Care Dentist.* 2006;26(3):116-20.
201. Sivasithamparam K, Young WG, Jirattanasopa V, Priest J, Khan F, Harbrow D, et al. Dental erosion in asthma: a case-control study from south east Queensland. *Aust Dent J.* 2002;47(4):298-303.
202. Sjovald S, Kanto J, Kangas L, Pakkanen A. Comparison of midazolam and flunitrazepam for night sedation. A randomised double-blind study. *Anaesthesia.* 1982;37(9):924-8.
203. Streckfus CF, Wu AJ, Ship JA, Brown LJ. Stimulated parotid salivary flow rates in normotensive, hypertensive, and hydrochlorothiazide-medicated. *J Oral Pathol Med.* 1994;23(6):280-3.
204. Tanna AP, Rademaker AW, Stewart WC, Feldman RM. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. *Arch Ophthalmol.* 2010;128(7):825-33.
205. Thiagarajan M, Chan CM, Fuang HG, Beng TS, Atiliyana MA, Yahaya NA. Symptom Prevalence and Related Distress in Cancer Patients Undergoing Chemotherapy. *Asian Pac J Cancer Prev.* 2016;17(1):171-6.
206. Thomson WM, Chalmers JM, Spencer AJ, Slade GD. Medication and dry mouth: findings from a cohort study of older people. *J Public Health Dent.* 2000;60(1):12-20.
207. Tiisanoja A, Syrjala AM, Komulainen K, Lampela P, Hartikainen S, Taipale H, et al. Anticholinergic burden and dry mouth among Finnish, community-dwelling older adults. *Gerodontology.* 2018;35(1):3-10.
208. Tomita Y, Osaki T. Gustatory impairment and salivary gland pathophysiology in relation to oral cancer treatment. *Int J Oral Maxillofac Surg.* 1990;19(5):299-304.
209. Torres SR, Pedrazas CH, Correia MP, Azevedo MN, Zamprogno T, Silva AJ, et al. Drugs or disease: evaluating salivary function in RA patients. *Pesqui Odontol Bras.* 2016;30(1):e106.
210. Turner L, Mupparapu M, Akintoye SO. Review of the complications associated with treatment of oropharyngeal cancer: a guide for the dental practitioner. *Quintessence Int.* 2013;44(3):267-79.
211. Tveito M, Correll CU, Bramness JG, Engedal K, Lorentzen B, Refsum H, et al. Correlates of major medication side effects interfering with daily performance: results from a cross-sectional cohort study of older psychiatric patients. *Int Psychogeriatr.* 2016;28(2):331-40.
212. van der Putten GJ, Brand HS, Schols JM, de Baat C. The diagnostic suitability of a xerostomia questionnaire and the association between xerostomia, hyposalivation and medication use in a group of nursing home residents. *Clin Oral Investig.* 2011;15(2):185-92.
213. van der Putten GJ, Brand HS, De Visschere LM, Schols JM, de Baat C. Saliva secretion rate and acidity in a group of physically disabled older care home residents. *Odontology.* 2013;101(1):108-15.
214. Velten DB, Zandonade E, Monteiro de Barros Miotto MH. Prevalence of oral manifestations in children and adolescents with cancer submitted to chemotherapy. *BMC Oral Health.* 2017;17(1):49.

215. Villa A, Wolff A, Aframian D, Vissink A, Ekstrom J, Proctor G, et al. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment. *Clin Oral Investig*. 2015;19(7):1563-80.
216. Villa A, Wolff A, Narayana N, Dawes C, Aframian DJ, Lynge Pedersen AM, et al. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction. *Oral Dis*. 2016;22(5):365-82.
217. Villa A, Abati S. Risk factors and symptoms associated with xerostomia: a cross-sectional study. *Aust Dent J*. 2011;56(3):290-5.
218. Wahlin YB. Salivary secretion rate, yeast cells, and oral candidiasis in patients with acute leukemia. *Oral Surg Oral Med Oral Pathol*. 1991;71(6):689-95.
219. Walker DJ, Mason O, Clemow DB, Day KA. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder. *Postgrad Med*. 2015;127(7):686-701.
220. Wang G, Zhang L, Lou S, Chen Y, Cao Y, Wang R, et al. Effect of Dexmedetomidine in Preventing Postoperative Side Effects for Laparoscopic Surgery: A Meta-Analysis of Randomized Controlled Trials and Trial Sequential Analysis (PRISMA). *Medicine (Baltimore)*. 2016;95(10):e2927.
221. Warren JB, Dollery CT, Sciberras D, Goldberg MR. Assessment of MK-467, a peripheral alpha 2-adrenergic receptor antagonist, with intravenous clonidine. *Clin Pharmacol Ther*. 1991;50(1):71-7.
222. Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, Berkowitz RI, Blakesley V, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. *Am J Psychiatry*. 2008;165(1):51-8.
223. Wilkins LH, Winternitz SR, Oparil S, Smith LR, Dustan HP. Lofexidine and clonidine in moderate essential hypertension. *Clin Pharmacol Ther*. 1981;30(6):752-07.
224. Wolff HA, Overbeck T, Roedel RM, Hermann RM, Herrmann MK, Kertesz T, et al. Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer. *J Cancer Res Clin Oncol*. 2009;135(7):961-7.
225. Wolff A, Fox PC, Ship JA, Atkinson JC, Macynski AA, Baum BJ. Oral mucosal status and major salivary gland function. *Oral Surg Oral Med Oral Pathol*. 1990;70(1):49-54.
226. Wu AJ, Ship JA. A characterization of major salivary gland flow rates in the presence of medications and systemic diseases. *Oral Surg Oral Med Oral Pathol*. 1993;76(3):301-6.
227. Yanai K, Rogala B, Chugh K, Paraskakis E, Pampura AN, Boev R. Safety considerations in the management of allergic diseases: focus on antihistamines. *Curr Med Res Opin*. 2012;28(4):623-42.
228. Zaslansky R, Schramm C, Stein C, Guthoff C, Schmidt-Westhausen AM. Topical application of morphine for wound healing and analgesia in patients with oral lichen planus: a randomized, double-blind, placebo-controlled study. *Clin Oral Investig*. 2018;22(1):305-11.
229. Ciancio SG. Medications: a risk factor for periodontal disease diagnosis and treatment. *J Periodontol*. 2005;76(11 Suppl):2061-5.
230. Gu L, Li S, He Y, Chen Y, Jiang Y, Peng Y, et al. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line *Helicobacter pylori* therapy in clinical practice: A pilot study. *Helicobacter*. 2019;24(4):e12594.
231. Gueiros LA, Soares MS, Leao JC. Impact of ageing and drug consumption on oral health. *Gerodontology*. 2009;26(4):297-301.
232. Hashimoto Y, Uno J, Miwa T, Kurihara M, Tanifuji H, Tensho M. Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients. *Psychiatry Clin Neurosci*. 2012;66(5):405-10.
233. Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, et al. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. *Am J Psychiatry*. 2016;173(9):876-86.
234. Lynge Pedersen AM, Nauntofte B, Smidt D, Torpet LA. Oral mucosal lesions in older people: relation to salivary secretion, systemic diseases and medications. *Oral Dis*. 2015;21(6):721-9.
235. Nam Y, Kim NH, Kho HS. Geriatric oral and maxillofacial dysfunctions in the context of geriatric syndrome. *Oral Dis*. 2018;24(3):317-24.
236. Spolarich AE. Risk management strategies for reducing oral adverse drug events. *J*. 2014;14 Suppl:87-94.e1.
237. Thomson WM. Dry mouth and older people. *Aust Dent J*. 2015;60 Suppl 1:54-63.

238. Turner MD. Hyposalivation and Xerostomia: Etiology, Complications, and Medical Management. *Dent Clin North Am.* 2016;60(2):435-43.
239. Chaves KM, Serrano-Blanco A, Ribeiro SB, Soares LA, Guerra GC, do Socorro Costa Feitosa Alves M, et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. *Psychiatr Q.* 2013;84(1):125-35.